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We describe the ﬁrst cases in the literature, to our knowl-edge, of pruritus as a paraneoplastic symptom of thy-
moma. The ﬁrst case is a 36-year-old woman who developed 
signiﬁcant generalized pruritus without rash during her sec-
ond pregnancy, which did not resolve after delivery and which 
was recalcitrant to topical steroids, antihistamines, and dry 
skin care. An extensive pruritus laboratory workup was per-
formed and was negative (Table 1). A chest computed tomog-
raphy (CT) performed 14 months after the onset of pruritus 
demonstrated a 7.5 × 4.3 cm anterior mediastinal mass that 
inﬁltrated the mediastinal fat and abutted the great vessels 
(Fig. 1A and B; Table 2). CT-guided ﬁne needle aspiration 
of the mass and a repeat core biopsy was nondiagnostic but 
consistent with thymic sampling. Immunohistochemistry for 
Hodgkin’s disease (HD) was negative. Based on the very high 
clinical suspicion of thymoma, she underwent three cycles of 
neoadjuvant cisplatin, cyclophosphamide, and doxorubicin 
chemotherapy with good response. Her pruritus resolved 3 
days after her ﬁrst cycle. She had a complete thymectomy, and 
ﬁnal pathology demonstrated a Masaoka-Koga stage II World 
Health Organization type B2 thymoma. The patient is under-
going surveillance, without recurrence of disease or pruritus, 
now 2 years postoperatively.
The second case is a 60-year-old woman who presented 
with 12 months of intermittent generalized pruritus without rash. 
A pruritus laboratory workup was negative (Table 1). A family 
history revealed HD in a maternal grandmother. A chest radio-
graph obtained routinely for work showed an anterior mediastinal 
mass. CT revealed a 9.2 × 7.7 × 11.7 cm mass, with indentation 
of the right atrium (Fig. 1C and D; Table 2). CT-guided core 
biopsy was consistent with thymoma. Clinically, she had a stages 
I or II thymoma and underwent a complete thymectomy. Final 
pathology demonstrated a Masaoka-Koga stage I World Health 
Organization type AB thymoma. Her pruritus resolved immedi-
ately after surgery. She is undergoing surveillance, without recur-
rence of disease or pruritus, now 2 years postoperatively.
DISCUSSION
To our knowledge, this is the ﬁrst case report of generalized 
pruritus as a paraneoplastic symptom heralding the diagnosis 
of thymoma. Paraneoplastic pruritus develops before a clini-
cally evident cancer, is not caused by direct effect of the tumor, 
and resolves after treatment.1 The most common malignancy 
associated with generalized pruritus is HD, where the preva-
lence rate is approximately 20% to 30%, and the severity of 
pruritus is associated with shorter survival.2 Generalized pru-
ritus without rash can be associated with multiple systemic 
diseases including liver disease, end-stage renal disease, and 
as a paraneoplastic symptom of malignancies.1 The standard 
workup for generalized pruritus without rash (as reported in 
Table 1) includes evaluation of complete blood count with dif-
ferential, liver function, renal function, and thyroid function 
and ruling out malignancy/lymphoma, viral infection (ie, HIV, 
hepatitis B/C), cholelithiasis, medication-related pruritus, and 
autoimmune conditions. Skin biopsy in the absence of a pri-
mary cutaneous lesion is nonspeciﬁc and is of low yield.
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Thymomas are frequently associated with autoim-
mune conditions and paraneoplastic syndromes including 
myasthenia gravis and pure red cell aplasia.3 Paraneoplastic 
skin conditions associated with thymoma that have been 
reported include mixed connective tissue disease, dermato-
myositis, systemic lupus erythematous, acrokeratosis, pem-
phigus, and lichen planus, which each have an associated 
clinically apparent rash.4
Thymoma is the most common neoplasm of the ante-
rior mediastinum and represents 20% of anterior mediastinal 
tumors.5 However, the differential diagnosis of an anterior 
mediastinal mass includes teratoma, seminoma, lymphoma, 
and also nonmalignant conditions. An anterior mediastinal 
mass in a patient with generalized pruritus is more likely to be 
attributed to HD than thymoma. Given the signiﬁcant upfront 
treatment differences between HD and thymoma, making the 
TABLE 1. Evaluation of Pruritus
Evaluation Case 1 Case 2
Distribution of pruritus Generalized but most bothersome on bilateral  
lower extremities and hands and feet
Generalized but most bothersome on 
upper extremities and back
Interventions attempted No resolution after a normal vaginal delivery
No improvement with antihistamines, topical 
moisturizers, or topical steroids
None
Constitutional symptoms, including fevers, night sweats,  
unintentional weight loss >10%
None None
Physical examination, including skin, lymph node,  
liver/spleen examination
Normal Normal
Thyroid-stimulating hormone Normal N/A
Complete blood count + differential Normal Normal
Serum chemistry/renal function Normal Normal
Serum liver function tests Normal N/A
Serum lactate dehydrogenase Normal N/A
Serum erythrocyte sedimentation rate and C-reactive protein Normal N/A
Other autoimmune work-upa N/A Negative
Hepatitis B + C panel Negative N/A
Other infectious work-upb Negative N/A
Right upper quadrant ultrasound Normal, no cholelithiasis N/A
Change in medications No No
aCase 2 had the following autoimmune workup: antinuclear antibody, rheumatoid factor, cyclic citrullinated peptide antibody IgG, anti-neutrophil cytoplasmic antibody, 
myeloperoxidase antibody, proteinase-3 antibody, SCL-70 antibody, Sjogren’s screen (anti-SS-A/Ro and anti-SS-B/La antibodies).
bCase 1 had toxoplasma, strongyloides, and quantiFERON-tuberculosis serologies sent.
FIGURE 1. Computed tomography 
axial views of case 1 demonstrating 
abutment of proximal great ves-
sels including aorta and pulmonary 
artery at different planes (A and B). 
Computed tomography (C) axial 
view and (D) coronal view of case 
2 demonstrating indentation of the 
right atrium.
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distinction between these two tumors is critical. The differen-
tial diagnosis of generalized pruritus in association with an 
anterior mediastinal mass should also include thymoma.
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TABLE 2. Characteristics of Cases
Characteristic Case 1 Case 2
Baseline CT imaging ﬁndings 7.5 × 4.3 cm left anterior mediastinal lobulated, 
homogeneous mass
Inﬁltrates the mediastinal fat
Abuts mediastinal vessels (superior vena cava, 
descending aorta, and main pulmonary artery)
9.2 × 7.7 × 11.7 cm right anteromedial mediastinal well-circumscribed, 
lobulated, heterogeneous mass
Moderate indentation of the right atrium





CT-guided biopsy (diagnostic for thymoma)
Clinical Masaoka-Koga stage III I or II
Neoadjuvant therapy Yes
CAP chemotherapy × 3 cycles
No
Operative ﬁndings Well-circumscribed main tumor mass towards the left 
of midline and a much smaller, apparently separate 
2 cm well-circumscribed tumor mass to the right of 
midline
Encapsulated tumor
Nodule palpated in right upper lobe
Type of resection Median sternotomy approach: complete thymectomy 
and radical mediastinal dissection
Median sternotomy approach: complete thymectomy, radical 
mediastinal dissection, and wedge excision of RUL lung nodule
Pathologic Masaoka-Koga  
stage
II
No clearly deﬁned capsule -well-deﬁned, discrete, 
microscopic foci of thymic tumor scattered 
throughout the surrounding mediastinal fat
I
Encapsulated tumor
Wedge RUL biopsy showed an organizing pneumonia pattern
WHO type B2 AB
Resection statusa R0 R0
Adjuvant therapy None None
FNA, ﬁne needle aspiration; CAP, cisplatin, cyclophosphamide, and doxorubicin; RUL, right upper lobe; WHO, World Health Organization.
aResection status: R0 = complete, R1 = microscopic, and R2 = macroscopic.
